286 related articles for article (PubMed ID: 33032648)
21. FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
Hassanein M; Almahayni MH; Ahmed SO; Gaballa S; El Fakih R
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):543-549. PubMed ID: 27450971
[TBL] [Abstract][Full Text] [Related]
22. FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects.
Hogan FL; Williams V; Knapper S
Curr Cancer Drug Targets; 2020; 20(7):513-531. PubMed ID: 32418523
[TBL] [Abstract][Full Text] [Related]
23. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Weis TM; Marini BL; Bixby DL; Perissinotti AJ
Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
[TBL] [Abstract][Full Text] [Related]
24. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Erba HP; Montesinos P; Kim HJ; Patkowska E; Vrhovac R; Žák P; Wang PN; Mitov T; Hanyok J; Kamel YM; Rohrbach JEC; Liu L; Benzohra A; Lesegretain A; Cortes J; Perl AE; Sekeres MA; Dombret H; Amadori S; Wang J; Levis MJ; Schlenk RF;
Lancet; 2023 May; 401(10388):1571-1583. PubMed ID: 37116523
[TBL] [Abstract][Full Text] [Related]
25. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
[TBL] [Abstract][Full Text] [Related]
26. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
Alvarado Y; Kantarjian HM; Luthra R; Ravandi F; Borthakur G; Garcia-Manero G; Konopleva M; Estrov Z; Andreeff M; Cortes JE
Cancer; 2014 Jul; 120(14):2142-9. PubMed ID: 24737502
[TBL] [Abstract][Full Text] [Related]
27. A real-world, retrospective, observational study examining treatment patterns and clinical outcomes in patients with FLT3m + AML in Japan.
Kiguchi T; Sakurai M; Tanaka Y; Kuramoto K; Kado Y; Sawada S; Mitomi T
Curr Med Res Opin; 2023 Nov; 39(11):1513-1522. PubMed ID: 37881860
[TBL] [Abstract][Full Text] [Related]
28. A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia.
Mohebbi A; Shahriyary F; Farrokhi V; Bandar B; Saki N
Leuk Res; 2024 Jun; 141():107505. PubMed ID: 38692232
[TBL] [Abstract][Full Text] [Related]
29. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
Stansfield LC; Pollyea DA
Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
[TBL] [Abstract][Full Text] [Related]
30. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T
Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
[TBL] [Abstract][Full Text] [Related]
32. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
Maifrede S; Nieborowska-Skorska M; Sullivan-Reed K; Dasgupta Y; Podszywalow-Bartnicka P; Le BV; Solecka M; Lian Z; Belyaeva EA; Nersesyan A; Machnicki MM; Toma M; Chatain N; Rydzanicz M; Zhao H; Jelinek J; Piwocka K; Sliwinski T; Stoklosa T; Ploski R; Fischer T; Sykes SM; Koschmieder S; Bullinger L; Valent P; Wasik MA; Huang J; Skorski T
Blood; 2018 Jul; 132(1):67-77. PubMed ID: 29784639
[TBL] [Abstract][Full Text] [Related]
33. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
McMahon CM; Ferng T; Canaani J; Wang ES; Morrissette JJD; Eastburn DJ; Pellegrino M; Durruthy-Durruthy R; Watt CD; Asthana S; Lasater EA; DeFilippis R; Peretz CAC; McGary LHF; Deihimi S; Logan AC; Luger SM; Shah NP; Carroll M; Smith CC; Perl AE
Cancer Discov; 2019 Aug; 9(8):1050-1063. PubMed ID: 31088841
[TBL] [Abstract][Full Text] [Related]
34. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in
Cortes JE; Tallman MS; Schiller GJ; Trone D; Gammon G; Goldberg SL; Perl AE; Marie JP; Martinelli G; Kantarjian HM; Levis MJ
Blood; 2018 Aug; 132(6):598-607. PubMed ID: 29875101
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.
Cortes JE; Kantarjian H; Foran JM; Ghirdaladze D; Zodelava M; Borthakur G; Gammon G; Trone D; Armstrong RC; James J; Levis M
J Clin Oncol; 2013 Oct; 31(29):3681-7. PubMed ID: 24002496
[TBL] [Abstract][Full Text] [Related]
36. Quizartinib for the treatment of acute myeloid leukemia.
Garcia-Horton A; Yee KW
Expert Opin Pharmacother; 2020 Dec; 21(17):2077-2090. PubMed ID: 32772726
[TBL] [Abstract][Full Text] [Related]
37. FLT3-targeted treatment for acute myeloid leukemia.
Arai Y; Chi S; Minami Y; Yanada M
Int J Hematol; 2022 Sep; 116(3):351-363. PubMed ID: 35532877
[TBL] [Abstract][Full Text] [Related]
38. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
39. [Breakthroughs in FLT3-mutated acute myeloid leukemia treatments].
Najima Y
Rinsho Ketsueki; 2023; 64(9):932-941. PubMed ID: 37793868
[TBL] [Abstract][Full Text] [Related]
40. Clinical Benefits and Safety of FMS-Like Tyrosine Kinase 3 Inhibitors in Various Treatment Stages of Acute Myeloid Leukemia: A Systematic Review, Meta-Analysis, and Network Meta-Analysis.
Xu Q; He S; Yu L
Front Oncol; 2021; 11():686013. PubMed ID: 34150652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]